BSD Medical's Cancer Systems Showcased in 3 Prestigious Hospitals and International Conference
Posted on: Monday, 19 September 2005, 15:01 CDT
SALT LAKE CITY, Sept. 19 /PRNewswire-FirstCall/ -- BSD Medical Corp. today announced that its premier cancer treatment system, the BSD-2000, drew central attention among the cancer therapy devices presented at this year's annual conference of CSCO (the Chinese Society of Clinical Oncology) held September 14-17 in Qingdao, China. Announced concurrent with the CSCO conference, new BSD-2000 systems have been purchased and are now being installed at Qingdao Central Hospital and the central hospital in Haerbin, China. These systems, and a system in Dalian, China, are part of a chain of BSD-2000 installations that BSD's distributor, Dalian Orientech, intends to use as prestigious medical centers to showcase the BSD-2000 in clinical practice, demonstrating its capabilities to the Chinese medical community.
Ray Lauritzen, a vice president of BSD Medical, said, "The BSD-2000 was unquestionably the center-stage cancer treatment device presented at the CSCO conference, and many physicians have expressed strong interest in bringing this advanced cancer treatment to their hospitals." CSCO is China's largest professional society for clinical oncologists, and is organized to provide continuous education for members and optimal care for cancer patients. CSCO members include physicians from more than 1,000 hospitals throughout the China mainland, Hong Kong and Taiwan.
The Chinese Society of Clinical Oncology provides an important influence for the advancement of cancer therapy not only in China, but also internationally. CSCO has formal ties and reciprocal membership with the European Society of Medical Oncology (ESMO), Europe's leading professional society for medical oncologists, and through the "Multidisciplinary Cancer Management Course" conducts cross-training with its American counterpart, the American Society of Clinical Oncology (ASCO).
The BSD-2000 by BSD Medical Corporation is drawing world attention as a technology that offers new hope in the war against cancer. BSD was awarded the 2005 cancer therapy device "Technology Innovation of the Year Award" by Frost and Sullivan for its development of the BSD-2000. A number of clinical trials have focused on the therapeutic power of the BSD-2000, including a study presented in the August issue of CANCER (104:763-770, 2005), the official Journal of the American Cancer Society, just circulated. CANCER published the results of a trial employing what the company has dubbed a tri-modality "super therapy" for treating cancer using BSD's advanced technology for treatments. Through a triple combination of radiation, chemotherapy and treatments with BSD-2000 systems that are designed to increase the effectiveness of both radiation and chemotherapy in addition to killing cancer directly, an international team of researchers at Duke University Medical Center, Norway and the Netherlands gave a powerful punch to the treatment of 68 patients who suffered from advanced cervical cancer. Ninety percent of them experienced a complete remission. For further information about BSD Medical and its technologies, visit the BSD website at http://www.bsdmedical.com/.
Statements contained in this press release that are not historical facts are forward-looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements, including expectations of future events, such as current expectations for the successful commercialization of developments by BSD for the treatment of cancer and other diseases and conditions, are subject to risks and uncertainties, detailed in the Company's filings with the Securities and Exchange Commission.
BSD Medical Corp.
CONTACT: Hyrum A. Mead of BSD Medical Corp., +1-801-972-5555, or fax,+1-801-972-5930, investor@bsdmc.com
Web site: http://www.bsdmedical.com/
Source: PRNewswire-FirstCall
Related Articles
- Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc.
- CMS, Inc., An Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
- Hospira Launches Generic Cancer Medication
- United Health Foundation Launches Series of Clinical Quality Improvement Grants to Medical Specialty Societies
- Handbook of Tuberculosis Clinics Diagnostics Therapy and Epidemiology is the Third Volume in This Comprehensive Series on This Deadly Airborne Disease
- Jamie Freedman, M.D., Ph.D. Joins Locus Pharmaceuticals As Chief Medical Officer and Vice President, Clinical Research & Regulatory Affairs
- Natrol Highlights Published Clinical Treatment Protocol Recommending Red Clover Isoflavones As a Safe Alternative to Hormone Replacement Therapy
- Largest Medical Center in Southern China Signs Affiliation Agreement With Americas Center for H5N1 Detection, Prevention and Research
- Esophagus Cancer Rate Drops Drastically in China's Most Prevalent Area: Report
- China Adopts Traditional Therapy, Medicine in Healing Drug Dependence
 |
 |
User Comments (0)
RSS Feeds